185 related articles for article (PubMed ID: 33335795)
1. Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC.
Chong W; Wang Z; Shang L; Jia S; Liu J; Fang Z; Du F; Wu H; Liu Y; Chen Y; Chen H
Mol Ther Nucleic Acids; 2021 Mar; 23():89-100. PubMed ID: 33335795
[TBL] [Abstract][Full Text] [Related]
2. Age-related mutational signature negatively associated with immune activity and survival outcome in triple-negative breast cancer.
Chen H; Chong W; Yang X; Zhang Y; Sang S; Li X; Lu M
Oncoimmunology; 2020 Jun; 9(1):1788252. PubMed ID: 32923150
[TBL] [Abstract][Full Text] [Related]
3. Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer.
Zhang W; Shi F; Kong Y; Li Y; Sheng C; Wang S; Wang Q
Cancer Med; 2022 Feb; 11(3):676-691. PubMed ID: 34862763
[TBL] [Abstract][Full Text] [Related]
4. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Zhang L; Han X; Shi Y
JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
[TBL] [Abstract][Full Text] [Related]
5. Sex-specific differences in immunogenomic features of response to immune checkpoint blockade.
Scott SC; Shao XM; Niknafs N; Balan A; Pereira G; Marrone KA; Lam VK; Murray JC; Feliciano JL; Levy BP; Ettinger DS; Hann CL; Brahmer JR; Forde PM; Karchin R; Naidoo J; Anagnostou V
Front Oncol; 2022; 12():945798. PubMed ID: 35992816
[TBL] [Abstract][Full Text] [Related]
6. Clock-like Mutation Signature May Be Prognostic for Worse Survival Than Signatures of UV Damage in Cutaneous Melanoma.
Fröhlich F; Ramelyte E; Turko P; Dzung A; Freiberger SN; Mangana J; Levesque MP; Dummer R
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568633
[TBL] [Abstract][Full Text] [Related]
7. The immune response-related mutational signatures and driver genes in non-small-cell lung cancer.
Chen H; Chong W; Teng C; Yao Y; Wang X; Li X
Cancer Sci; 2019 Aug; 110(8):2348-2356. PubMed ID: 31222843
[TBL] [Abstract][Full Text] [Related]
8. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
9. Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations.
Zhang W; Tang Y; Guo Y; Kong Y; Shi F; Sheng C; Wang S; Wang Q
NPJ Precis Oncol; 2022 Jun; 6(1):46. PubMed ID: 35739249
[TBL] [Abstract][Full Text] [Related]
10. ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer.
Zhang J; Zhou N; Lin A; Luo P; Chen X; Deng H; Kang S; Guo L; Zhu W; Zhang J
Cancer Immunol Immunother; 2021 Jan; 70(1):137-151. PubMed ID: 32653938
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice.
Campesato LF; Barroso-Sousa R; Jimenez L; Correa BR; Sabbaga J; Hoff PM; Reis LF; Galante PA; Camargo AA
Oncotarget; 2015 Oct; 6(33):34221-7. PubMed ID: 26439694
[TBL] [Abstract][Full Text] [Related]
12. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Three Sequencing Panels Used for the Assessment of Tumor Mutational Burden in NSCLC Reveals Low Comparability.
Heeke S; Benzaquen J; Hofman V; Long-Mira E; Lespinet V; Bordone O; Marquette CH; Delingette H; Ilié M; Hofman P
J Thorac Oncol; 2020 Sep; 15(9):1535-1540. PubMed ID: 32450274
[TBL] [Abstract][Full Text] [Related]
14. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
15.
Zhang W; Lin Z; Shi F; Wang Q; Kong Y; Ren Y; Lyu J; Sheng C; Li Y; Qin H; Wang S; Wang Q
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884556
[TBL] [Abstract][Full Text] [Related]
16.
Ma SC; Zhu HB; Wang J; Zhang YP; Guo XJ; Long LL; Guo ZQ; Wu DH; Dong ZY; Bai X
Front Oncol; 2021; 11():666145. PubMed ID: 34221982
[TBL] [Abstract][Full Text] [Related]
17. Data Interoperability of Whole Exome Sequencing (WES) Based Mutational Burden Estimates from Different Laboratories.
Qiu P; Pang L; Arreaza G; Maguire M; Chang KC; Marton MJ; Levitan D
Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27136543
[TBL] [Abstract][Full Text] [Related]
18. Association of
Chen H; Chong W; Wu Q; Yao Y; Mao M; Wang X
Front Immunol; 2019; 10():1113. PubMed ID: 31164891
[No Abstract] [Full Text] [Related]
19. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
[TBL] [Abstract][Full Text] [Related]
20. Immune signatures in cutaneous melanoma correlate with survival independently of immunotherapy treatment.
Johansson PA; Hayward NK; Pritchard AL
Pigment Cell Melanoma Res; 2023 Mar; 36(2):246-251. PubMed ID: 36617535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
